ABBVIE
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 2013-01-01
- Employees
- -
- Market Cap
- $346B
- Website
- http://www.abbvie.com
Physical Activity in Patients With Rheumatoid Arthritis Treated With Adalimumab in Routine Clinical Practice
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2012-12-25
- Last Posted Date
- 2017-03-06
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 462
- Registration Number
- NCT01756235
Global REsponsE During iNFusIon of a gEl With LevoDopa/Carbidopa
- Conditions
- Parkinson's Disease
- First Posted Date
- 2012-12-21
- Last Posted Date
- 2018-08-10
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 148
- Registration Number
- NCT01754129
Impact of Adalimumab (Humira®) Therapy on Selected Health Care Resource Utilization and Sick Leave in Patients With Ankylosing Spondylitis in Clinical Practice
- Conditions
- Ankylosing Spondylitis
- First Posted Date
- 2012-12-21
- Last Posted Date
- 2017-03-06
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 452
- Registration Number
- NCT01754727
Study in Rheumatoid Arthritis for Subjects Who Completed Preceding Study M13-390 With Adalimumab
- Conditions
- Rheumatoid Arthritis
- Interventions
- Biological: New formulation adalimumab
- First Posted Date
- 2012-12-19
- Last Posted Date
- 2014-10-29
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 88
- Registration Number
- NCT01752855
- Locations
- 🇺🇸
Site Reference ID/Investigator# 92114, Charleston, South Carolina, United States
🇩🇪Site Reference ID/Investigator# 92073, Ratingen, Germany
🇺🇸Site Reference ID/Investigator# 92113, Mesa, Arizona, United States
Investigation of the Effectiveness of Sevoflurane Anaesthesia in Difficult to Intubate Egyptian Patients
- Conditions
- Intubation; Difficult
- First Posted Date
- 2012-12-17
- Last Posted Date
- 2016-03-01
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 97
- Registration Number
- NCT01749631
A Post Marketing Observational Study of Activities of Daily Living in Advanced Parkinson's Disease Patients With Early Troublesome Motor Fluctuations and Treated With Duodopa - a Multi-country Study
- Conditions
- Parkinson's Disease
- First Posted Date
- 2012-12-12
- Last Posted Date
- 2016-10-13
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 64
- Registration Number
- NCT01747655
A Study of ABT-414 in Subjects With Solid Tumors
- First Posted Date
- 2012-12-05
- Last Posted Date
- 2017-11-20
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 57
- Registration Number
- NCT01741727
- Locations
- 🇺🇸
Site Reference ID/Investigator# 117516, Boston, Massachusetts, United States
🇺🇸Site Reference ID/Investigator# 90333, Scottsdale, Arizona, United States
🇺🇸Site Reference ID/Investigator# 83156, Chicago, Illinois, United States
A Study in Healthy Adults and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics After Multiple Doses of ABT-494
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2012-12-05
- Last Posted Date
- 2017-11-20
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 67
- Registration Number
- NCT01741493
- Locations
- 🇺🇸
Site Reference ID/Investigator# 95815, Duncansville, Pennsylvania, United States
🇺🇸Site Reference ID/Investigator# 95817, Miami, Florida, United States
🇺🇸Site Reference ID/Investigator# 95816, Cincinnati, Ohio, United States
Efficacy and Safety Study of ABT-436 in Major Depressive Disorder
- Conditions
- Major Depressive Disorder
- Interventions
- First Posted Date
- 2012-12-04
- Last Posted Date
- 2013-10-08
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 19
- Registration Number
- NCT01741142
- Locations
- 🇺🇸
Site Reference ID/Investigator# 87225, South Miami, Florida, United States
🇺🇸Site Reference ID/Investigator# 87226, Portland, Oregon, United States
🇺🇸Site Reference ID/Investigator# 88876, Seattle, Washington, United States
Assessment of Clinical Effectiveness and Safety of Adalimumab and High Dose Methotrexate in Routine Clinical Practice
- First Posted Date
- 2012-11-29
- Last Posted Date
- 2019-07-02
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 346
- Registration Number
- NCT01736189